Pricing Log in Create free account
Friday 6 November 2026 Export SOLV’s income statement to Excel — free account

Solventum Corporation

SOLV Healthcare Medical Instruments & Supplies

Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024.

Revenue
−7.01%
EPS
−101.0%
Free cash flow
+561.9%
Total debt
−90.1%

Quarter to September 2026, against a year earlier

90.48 3.30 +3.79%
Market cap
$14.8B
P/E
102×
Fwd P/E
47.7×
Dividend yield
—
F-score
5/9
Altman Z
2.22
Beneish M
−2.07
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Solventum Corporation 10-Q filed Nov 6, 2025

Fiscal Q3 2025 · Period ended Sep 30, 2025 · Filed · accepted 5:14 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 8, 2025: 14 added · 8 removed · 33 modified; 15 with only figures updated; 3 moved without change

  1. Modified · Operating Segments and Sales Change Information

    Solventum manages its operations in fourthree business segments: MedSurg, Dental Solutions, and Health Information Systems, and Purification and Filtration. On February 25, 2025, the Company entered into a Transaction Agreement to sell its Purification and Filtration business to Thermo Fisher Scientific Inc. (“Buyer”) for $4.1 billion. On June 25, 2025, the Company and Buyer entered into an additional Agreement to exclude the Company’s Water Business from the scope of the Purification and Filtration business Business to be acquired by Buyer and reduce the cash consideration at closing . On September 1, 2025, Solventum completed the sale of the transactionBusiness to approximately $4.0 billion. The closing of the transaction is expected to be completed by Buyer in accordance with the endterms of 2025, subject to regulatory approvals and customary closing conditionsthe Agreement. The company intends cash consideration paid to use the net proceeds from the transaction primarilySolventum at closing was approximately $4 billion. Refer to pay down a portion of the Company’s outstanding debt through the pay down of our term loan and bond buybacksNote 3, “Acquisitions and Divestitures” for additional information.